Savara says Europe, Australia grant MOLBREEVI liquid formulation patents through 2041
SVRA•Patent coverage expands for MOLBREEVI outside the US
Savara says it secured granted patents in Europe and Australia covering the liquid formulation of MOLBREEVI, extending protection through March 2041.
- The Europe grant is European patent No. 4121000.
- The Australia grant is patent No. 62/990,810.
- The announcement strengthens intellectual property coverage for MOLBREEVI outside the US as Savara advances related US filings.
- Savara cited a separate joint European patent with PARI for a MOLBREEVI drug-device combination, running through March 2043.
